moxifloxacin has been researched along with Experimental Pneumococcal Meningitis in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cottagnoud, M; Cottagnoud, P; Schaffner, T; Stucki, A; Winkelmann, V | 1 |
| Davydov, A; Karpov, I; Salavei, M; Titov, L | 1 |
| Böttcher, T; Brocke, VV; Djukic, M; Eiffert, H; Gerber, J; Nau, R; Wellmer, A | 1 |
| Brück, W; Chen, V; Dalhoff, A; Kohlsdorfer, C; Nau, R; Schmidt, H; Schneider, O; Stuertz, K; Trostdorf, F | 1 |
| Frimodt-Møller, N; Knudsen, JD; Ostergaard, C; Sørensen, TK | 1 |
| Bianco, G; Capone, A; Cassone, M; Tarasi, A; Tarasi, D; Venditti, M | 1 |
| Eiffert, H; Mäder, M; Nau, R; Schmidt, H; Stuertz, K; Trostdorf, F | 1 |
7 other study(ies) available for moxifloxacin and Experimental Pneumococcal Meningitis
| Article | Year |
|---|---|
Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall.
Topics: Animals; Anti-Bacterial Agents; Bacteriolysis; Ceftriaxone; Cell Wall; Cerebrospinal Fluid; Choline; Daptomycin; Disease Models, Animal; Humans; Meningitis, Pneumococcal; Microbial Sensitivity Tests; Penicillin Resistance; Rabbits; Streptococcus pneumoniae; Treatment Outcome; Tritium | 2007 |
First report of ceftriaxone-resistant Streptococcus pneumoniae meningitis in Belarus.
Topics: Ceftriaxone; Dexamethasone; Drug Resistance, Bacterial; Humans; Intensive Care Units; Male; Meningitis, Pneumococcal; Meropenem; Middle Aged; Molecular Typing; Moxifloxacin; Republic of Belarus; Streptococcus pneumoniae; Treatment Outcome | 2017 |
Moxifloxacin in experimental Streptococcus pneumoniae cerebritis and meningitis.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Ceftriaxone; Disease Models, Animal; Drug Administration Schedule; Fluoroquinolones; Injections, Subcutaneous; Male; Meningitis, Pneumococcal; Mice; Mice, Inbred C57BL; Moxifloxacin; Quinolines; Treatment Outcome | 2005 |
Moxifloxacin in the therapy of experimental pneumococcal meningitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Fluoroquinolones; Meningitis, Pneumococcal; Moxifloxacin; Pneumococcal Infections; Quinolines; Quinolones; Rabbits; Streptococcus pneumoniae | 1998 |
Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ceftriaxone; Cephalosporins; Drug Evaluation; Fluoroquinolones; Meningitis, Pneumococcal; Microbial Sensitivity Tests; Moxifloxacin; Penicillin Resistance; Protein Binding; Quinolines; Quinolones; Rabbits; Streptococcus pneumoniae; Time Factors; Vancomycin | 1998 |
Comparative in-vitro activity of moxifloxacin, penicillin, ceftriaxone and ciprofloxacin against pneumococci isolated from meningitis.
Topics: Anti-Bacterial Agents; Aza Compounds; Ceftriaxone; Ciprofloxacin; Fluoroquinolones; Humans; Meningitis, Pneumococcal; Microbial Sensitivity Tests; Moxifloxacin; Penicillins; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 1999 |
Lower lipoteichoic and teichoic acid CSF concentrations during treatment of pneumococcal meningitis with non-bacteriolytic antibiotics than with ceftriaxone.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ceftriaxone; Cephalosporins; Disease Models, Animal; Fluoroquinolones; Immunoenzyme Techniques; Lipopolysaccharides; Meningitis, Pneumococcal; Moxifloxacin; Naphthyridines; Polysaccharides, Bacterial; Quinolines; Rabbits; Reference Values; Rifabutin; Teichoic Acids; Virginiamycin | 1999 |